(c) “BD Agreement” means a significant licensing arrangement with a pharmaceutical company that will include an initial (“up-front”) payment to the Company in an amount in the double-digits millions of dollars and will arrange for such pharmaceutical company to undertake the continuing development of the Company’s Brilacidin compound in the indication of Oral Mucositis, including the conducting and funding of clinical trials aiming towards the filing of an NDA”
"It doesn't rule out a deal for IBD, but it shows the company feels the immediate prospects, or industry interests they are perceiving, are best for that one indication, OM."
Once again there's an assumption in that thought that the terms of the Agreement were driven by IPIX's desires. It could be that the BD Agreement indication was dictated by Aspire based on THEIR view of the prospects for OM versus IBD.
News 
Market Data 
Discover 
